STLN · Starling Oncology, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$2.21M | Six Months Ended June 30 | — |
|
|
|||
| Affiliated and Network Clinics | 301 | Three Months Ended June 30 | — |
| Capitated lives added through California exclusivity agreement | 230,000 | Q2 2026 | — |
| Free Cash Flow non-GAAP | $9.53M | Six Months Ended June 30, 2026 | — |
| Lives under value-based contracts | 2.1M | Three Months Ended June 30 | — |
| Medical loss ratio related to capitated contracts non-GAAP | 85.5% | Three Months Ended June 30, 2026 | — |
| Specialty Pharmacy revenue | 58% | the quarter ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STLN
this stock
Starling Oncology, Inc.
|
$652.26M | +79.8% | +27.8% | — | 7.0% |
|
HCA
HCA Healthcare, Inc.
|
$89.84B | -11.8% | +7.1% | 14.0 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.69B | -5.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.76B | +36.0% | +0.9% | 10.4 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.51B | -1.1% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STLN | +3.3% | +17.9% | +123.8% | +31.7% | +79.8% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | +3.7% | +15.3% | +113.1% | +29.0% | +67.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.